For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of this treatment and Attruby represents a significant advancement . These groundbreaking therapies protect the transthyretin protein, halting its damaging build-up and alleviating the burden of the condition . Patients are now seeing b